Gynesonics is a women's healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids. Gynesonics has developed the VizAblate System, a transcervical, ultrasound-guided ablation system for the treatment of uterine fibroids. VizAblate has the CE Mark in the European Union and is currently limited to investigational use in the United States.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/20/13 | $21,000,000 | Series D |
Abingworth Advanced Technology Ventures Correlation Ventures HBM Partners InterWest Partners | undisclosed |
| 07/23/15 | $43,000,000 |
Abingworth Advanced Technology Ventures Correlation Ventures Endeavor Vision HBM Partners HealthCrest Hercules Technology Growth Capital InterWest Partners | undisclosed | |
| 01/03/19 | $75,000,000 | Venture |
Abingworth Advanced Technology Ventures Bain Capital  Correlation Ventures Endeavor Vision HBM Partners HealthCrest Hercules Technology Growth Capital InterWest Partners | undisclosed |
